Credit Suisse’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Credit Suisse’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-19,049	Closed	-$2.04M	–	3306
2023 Q1	$2.04M	Buy	19,049 +2,089	+12%	+$240K	﹤0.01%	1853
2022 Q4	$1.87M	Buy	16,960 +7,893	+87%	+$512K	﹤0.01%	1925
2022 Q3	$535K	Buy	9,067 +142	+2%	+$6.5K	﹤0.01%	2744
2022 Q2	$251K	Sell	8,925 -2,110	-19%	-$61.2K	﹤0.01%	3240
2022 Q1	$417K	Sell	11,035 -1,104	-9%	-$43.6K	﹤0.01%	3074
2021 Q4	$480K	Buy	+12,139	New	+$380K	﹤0.01%	3843

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Credit Suisse's RXDX Position: Q2 2023 in Review

Credit Suisse sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 19,049 shares — an estimated $2.04M sold.

Credit Suisse first reported a position in RXDX in Q4 2021 and held it in 6 quarters. The position peaked at $2.04M in Q1 2023. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Credit Suisse reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Credit Suisse sold 19,049 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $2.04M.
Credit Suisse first reported a position in Prometheus Biosciences, Inc. Common Stock in Q4 2021 and held it in 6 quarters.
Credit Suisse's Prometheus Biosciences, Inc. Common Stock position peaked at $2.04M in Q1 2023.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Credit Suisse's 13F filing for Q2 2023, filed 11 Aug 2023.